| pubmed-article:20545388 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:20545388 | lifeskim:mentions | umls-concept:C0009170 | lld:lifeskim |
| pubmed-article:20545388 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:20545388 | lifeskim:mentions | umls-concept:C0004927 | lld:lifeskim |
| pubmed-article:20545388 | lifeskim:mentions | umls-concept:C1707455 | lld:lifeskim |
| pubmed-article:20545388 | lifeskim:mentions | umls-concept:C1555903 | lld:lifeskim |
| pubmed-article:20545388 | lifeskim:mentions | umls-concept:C0683476 | lld:lifeskim |
| pubmed-article:20545388 | lifeskim:mentions | umls-concept:C1521840 | lld:lifeskim |
| pubmed-article:20545388 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:20545388 | pubmed:dateCreated | 2010-6-15 | lld:pubmed |
| pubmed-article:20545388 | pubmed:abstractText | New data support use of levodopa pharmacotherapy with behavioral contingency management (CM) as one efficacious combination in cocaine dependence disorder treatment. A potential mechanism of the combined treatment effects may be related to dopamine-induced enhancement of the saliency of contingently delivered reinforcers. Evidence to support this mechanism was sought by evaluating levodopa-enhancing effects across distinct CM conditions that varied in behavioral targets. A total of 136 treatment-seeking, cocaine dependent subjects participated in this 12-week, randomized, placebo-controlled trial of levodopa (vs. placebo) administered in combination with one of three behavioral CM conditions. In the CM-URINE condition, subjects received cash-valued vouchers contingent on cocaine-negative urine toxicology results. In the CM-ATTEND condition, the same voucher schedule was contingent on attending thrice weekly clinic visits. In the CM-MEDICATION condition, the same voucher schedule was contingent on Medication Event Monitoring Systems- and riboflavin-based evidence of pill-taking behavior. Primary outcomes associated with each CM target behavior were analyzed using generalized linear mixed models for repeated outcomes. CM responding in the CM-ATTEND and CM-MEDICATION conditions showed orderly effects, with each condition producing corresponding changes in targeted behaviors, regardless of medication condition. In contrast, CM responding in the CM-URINE condition was moderated by medication, with levodopa-treated subjects more likely to submit cocaine-negative urines. These findings specify the optimal target behavior for CM when used in combination with levodopa pharmacotherapy. | lld:pubmed |
| pubmed-article:20545388 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20545388 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20545388 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20545388 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20545388 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20545388 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20545388 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20545388 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20545388 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20545388 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20545388 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20545388 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20545388 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20545388 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20545388 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20545388 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20545388 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20545388 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20545388 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20545388 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20545388 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20545388 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20545388 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20545388 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20545388 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20545388 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20545388 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20545388 | pubmed:language | eng | lld:pubmed |
| pubmed-article:20545388 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20545388 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:20545388 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20545388 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20545388 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20545388 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20545388 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:20545388 | pubmed:month | Jun | lld:pubmed |
| pubmed-article:20545388 | pubmed:issn | 1936-2293 | lld:pubmed |
| pubmed-article:20545388 | pubmed:author | pubmed-author:StottsAngela... | lld:pubmed |
| pubmed-article:20545388 | pubmed:author | pubmed-author:SchmitzJoy... | lld:pubmed |
| pubmed-article:20545388 | pubmed:author | pubmed-author:MoellerF... | lld:pubmed |
| pubmed-article:20545388 | pubmed:author | pubmed-author:GreenCharles... | lld:pubmed |
| pubmed-article:20545388 | pubmed:author | pubmed-author:LindsayJan... | lld:pubmed |
| pubmed-article:20545388 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:20545388 | pubmed:volume | 18 | lld:pubmed |
| pubmed-article:20545388 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:20545388 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:20545388 | pubmed:pagination | 238-44 | lld:pubmed |
| pubmed-article:20545388 | pubmed:dateRevised | 2011-9-26 | lld:pubmed |
| pubmed-article:20545388 | pubmed:meshHeading | pubmed-meshheading:20545388... | lld:pubmed |
| pubmed-article:20545388 | pubmed:meshHeading | pubmed-meshheading:20545388... | lld:pubmed |
| pubmed-article:20545388 | pubmed:meshHeading | pubmed-meshheading:20545388... | lld:pubmed |
| pubmed-article:20545388 | pubmed:meshHeading | pubmed-meshheading:20545388... | lld:pubmed |
| pubmed-article:20545388 | pubmed:meshHeading | pubmed-meshheading:20545388... | lld:pubmed |
| pubmed-article:20545388 | pubmed:meshHeading | pubmed-meshheading:20545388... | lld:pubmed |
| pubmed-article:20545388 | pubmed:meshHeading | pubmed-meshheading:20545388... | lld:pubmed |
| pubmed-article:20545388 | pubmed:meshHeading | pubmed-meshheading:20545388... | lld:pubmed |
| pubmed-article:20545388 | pubmed:meshHeading | pubmed-meshheading:20545388... | lld:pubmed |
| pubmed-article:20545388 | pubmed:meshHeading | pubmed-meshheading:20545388... | lld:pubmed |
| pubmed-article:20545388 | pubmed:meshHeading | pubmed-meshheading:20545388... | lld:pubmed |
| pubmed-article:20545388 | pubmed:meshHeading | pubmed-meshheading:20545388... | lld:pubmed |
| pubmed-article:20545388 | pubmed:meshHeading | pubmed-meshheading:20545388... | lld:pubmed |
| pubmed-article:20545388 | pubmed:meshHeading | pubmed-meshheading:20545388... | lld:pubmed |
| pubmed-article:20545388 | pubmed:meshHeading | pubmed-meshheading:20545388... | lld:pubmed |
| pubmed-article:20545388 | pubmed:year | 2010 | lld:pubmed |
| pubmed-article:20545388 | pubmed:articleTitle | Contingency management and levodopa-carbidopa for cocaine treatment: a comparison of three behavioral targets. | lld:pubmed |
| pubmed-article:20545388 | pubmed:affiliation | Department of Psychiatry and Behavioral Sciences, University of Texas-Houston, Houston, TX, USA. joy.m.schmitz@uth.tmc.edu | lld:pubmed |
| pubmed-article:20545388 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:20545388 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:20545388 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:20545388 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| pubmed-article:20545388 | pubmed:publicationType | Research Support, N.I.H., Extramural | lld:pubmed |
